Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell-Off

New insider activity at Alnylam Pharma ( (ALNY) ) has taken place on January 14, 2026.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Several top executives at Alnylam Pharmaceuticals have recently cashed out notable amounts of company stock in a concentrated wave of insider selling. EVP Chief R&D officer Pushkal Garg sold 1,510 shares for $547,928, while EVP & CCO Tolga Tanguler also disposed of 1,510 shares, raising $547,927. CSO & EVP, Head of Research Kevin Joseph Fitzgerald matched that activity with the sale of 1,510 shares worth $547,927. Financial leadership joined in as EVP & CFO Jeffrey V. Poulton sold 2,780 shares for $1,008,765. The largest transaction came from CEO Yvonne Greenstreet, who sold 9,577 shares of Alnylam Pharma stock, generating proceeds of $3,475,156. Collectively, these sales highlight a significant round of profit-taking among the company’s highest-ranking insiders. Recent Updates on ALNY stock In the last 24 hours, Alnylam Pharmaceuticals has drawn renewed analyst attention as Oppenheimer initiated coverage with a positive stance driven largely by the strong commercial performance of its drug Amvuttra in ATTR-CM, which generated about $300M in its second full quarter post-launch. While the stock has been under pressure due to broader market concerns about a possible slowdown in Amvuttra’s growth and increasing payer pushback, Oppenheimer’s view is that these fears are overdone: they expect only typical seasonality to weigh on Q4 2025 results and believe Amvuttra can continue to exceed growth expectations. The firm also anticipates that upcoming sales results and guidance updates could act as catalysts for further upside in the share price, framing recent target and rating actions around the strength and durability of Amvuttra’s trajectory versus perceived market risks, rather than any deterioration in the underlying business. Spark’s Take on ALNY Stock According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral. Alnylam Pharma’s overall score is driven by strong earnings call results and robust revenue growth, tempered by high leverage and valuation concerns. The technical indicators suggest moderate market sentiment, while the high P/E ratio indicates potential overvaluation. To see Spark’s full report on ALNY stock, click here. More about Alnylam Pharma YTD Price Performance: -6.96% Average Trading Volume: 1,332,968 Technical Sentiment Signal: Buy Current Market Cap: $49B